TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04081701

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ga68-DOTATATE-PET/MRI
Description: In patients with meningioma who are undergoing surgical planning, subjects will undergo a PET scan at the time of their pretreatment or preoperative standard of care MRI exam, prior to surgery performed for research purposes. Instead of the standard of care MRI exam, subjects will undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.There will be up to two follow-up with Ga68-DOTATATE PET/MRI scans performed as standard of care.~In patients with SSTR-positive CNS tumors that are non-meningioma, MRI is often performed to assess extent of disease. Subjects may be asked to undergo a PET scan for research purposes at the time of their standard of care MRI. Instead of the standard of care MRI exam, they may be asked to undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ga68-DOTATATE-PET/MRI
Description: In patients with meningioma who are undergoing surgical planning, subjects will undergo a PET scan at the time of their pretreatment or preoperative standard of care MRI exam, prior to surgery performed for research purposes. Instead of the standard of care MRI exam, subjects will undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.There will be up to two follow-up with Ga68-DOTATATE PET/MRI scans performed as standard of care.~In patients with SSTR-positive CNS tumors that are non-meningioma, MRI is often performed to assess extent of disease. Subjects may be asked to undergo a PET scan for research purposes at the time of their standard of care MRI. Instead of the standard of care MRI exam, they may be asked to undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.
Study: NCT01847495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 40mg/m2 x 3-5 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife
Description: 45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
Study: NCT03367702

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT
Study: NCT01189253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT00479362

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Permanent pacemaker
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.

Intervention type: DEVICE
Group type: OTHER
Intervention: Permanent pacemaker
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
Study: NCT02812420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo cystectomy with pelvic lymph node dissection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT04293653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol for patients above 75 undergoing emergency laparotomy or laparoscopy
Description: See above section
Study: NCT01189253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study: NCT00479362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter-defibrillator
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter-defibrillator
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Implantable Cardioverter-defibrillator
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Cardioverter-defibrillator
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
Study: NCT04819828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy
Description: A single session of extracorporeal shock wave lithotripsy: the session will be finished upon reaching a maximum of 4,000 shocks or if a complete fragmentation of the kidney stone is observed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy
Description: A single session of extracorporeal shock wave lithotripsy: the session will be finished upon reaching a maximum of 4,000 shocks or if a complete fragmentation of the kidney stone is observed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Standard treatment for analgesia: oral diclofenac (75 mg/12 h) as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Standard treatment for analgesia: oral diclofenac (75 mg/12 h) as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Oral tamsulosin (0.4 mg/day) for eight weeks.
Study: NCT01690962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegan diet and vitamin B12 supplement
Description: A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
Study: NCT01189253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT01690962

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 supplement
Description: A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
Study: NCT01094899

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiography
Description: Radiography, microscanner, osteodensitometry

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiography
Description: Radiography, microscanner, osteodensitometry

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiography
Description: Radiography, microscanner, osteodensitometry

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiography
Description: Radiography, microscanner, osteodensitometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine and Blood sampling
Description: mainly dosage of bones metabolism

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine and Blood sampling
Description: mainly dosage of bones metabolism

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine and Blood sampling
Description: mainly dosage of bones metabolism

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine and Blood sampling
Description: mainly dosage of bones metabolism

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echography
Description: body bones echography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echography
Description: body bones echography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echography
Description: body bones echography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echography
Description: body bones echography
Study: NCT02077712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: 1 or 2 ug/kg of intranasal dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: 1 or 2 ug/kg of intranasal dexmedetomidine
Study: NCT04151641

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNGDPF
Description: Standardized mangosteen extract in dry powder form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNGDPF
Description: Standardized mangosteen extract in dry powder form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNGEF
Description: Standardized mangosteen extract in encapsulated form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNGEF
Description: Standardized mangosteen extract in encapsulated form
Study: NCT01933425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugammadex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01187875

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Fiber free control
Description: Dextrin control administered in a muffin treatment.
Study: NCT05659121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic exoskeleton training
Description: robotic exoskeleton training using EksoGT will be incorporated into subject's conventional physiotherapy training.
Study: NCT04445077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia Competence Education for care home setting
Description: The intervention is a competency-based education program for care home staff who provide dementia care in Mainland China.

Intervention type: OTHER
Group type: OTHER
Intervention: Printed educational materials
Description: The educational materials will be delivered to the participants in the control group for their self-study.
Study: NCT02862210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
Study: NCT01962662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Description: EMG biofeedback assisted tibialis anterial force level control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Description: EMG biofeedback assisted tibialis anterial force level control

Intervention type: OTHER
Group type: OTHER
Intervention: U/E exercise
Description: strengthening and stretching
Study: NCT01667744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: 10 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram
Description: 10 mg/day
Study: NCT06456723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FET-βAG-TOCA
Description: Single I.V. administration of a \[18F\]fluoroethyl triazole \[Tyr3\]Octreotate (\[18F\]-FET-βAG-TOCA) - maximum injected dose of 370MBq - followed PET/CT imaging.
Study: NCT04341610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Product
Description: 100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stem Cell Product
Description: 100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline
Study: NCT00248677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Family-Based Intervention
Description: Behavioral family intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent-Based Intervention
Description: Behavioral Parent-Only Intervention
Study: NCT02440724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Winged stent (partially covered)
Description: A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Winged stent (uncovered)
Description: A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
Study: NCT04346225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized C13
Description: Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes
Study: NCT01187875

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hi-maize resistant starch 9g
Description: 9g Hi-maize resistant starch administered in a muffin treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novalose 330 resistant starch 9g
Description: 9g Novalose 330 resistant starch administered in a muffin treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4.5g Hi-maize resistant starch and 4.5g Novalose 330
Description: 4.5g Hi-maize and 4.5g Novalose 330 in a muffin treatment.
Study: NCT01623284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 PiB
Description: One time intravenous administration of 740 megabecquerel (MBq) of \[N-methyl-11C\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FDG
Description: One time intravenous administration of 629 megabecquerel (MBq) of \[18-F\]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
Study: NCT03830411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
Study: NCT00398905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 2,5 mg twice daily (5 mg total daily dose)
Study: NCT04346225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized C13
Description: Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body
Study: NCT04150913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Subcutaneous, dosage per protocol. Day 0 through Day 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Once, intravenous infusion, dosage per protocol
Study: NCT02510417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSTs
Description: most closely HLA-matched multivirus-specific T cell lines obtained from a bank of allogeneic virus-specific T cell lines (VSTs) have antiviral activity against three viruses: EBV, CMV and adenovirus
Study: NCT03595800

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hematopoietic stem cells transplantation
Description: Allogeneic Hematopoietic stem cells transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cells transplantation
Description: Allogeneic Hematopoietic stem cells transplantation
Study: NCT05124366

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: dental prophylaxis + oral hygiene instructions
Description: Follow up: 2 weeks and 4 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental prophylaxis + oral hygiene instructions
Description: Follow up: 2 weeks and 4 weeks
Study: NCT02376114

Intervention type: DRUG
Group type: OTHER
Intervention: Ginkgo biloba
Description: The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of Ginkgo or a placebo twice daily by mouth for two weeks. The placebo consisted of 40 mg of corn starch. Ginkgo and the placebo were encapsulated to ensure identical appearance.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to Ginkgo biloba
Study: NCT03933592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior block
Description: after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally, until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 mint before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural
Description: In group I: thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
Study: NCT00974558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: handheld fan directed to cheeks
Description: Handheld fan directed to cheeks for 5 minutes
Study: NCT04570748

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsule repair
Description: Direct anterior hip arthroplasty with or without capsule repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: capsulectomy
Description: capsulectomy without repair
Study: NCT02802852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic calf compression
Description: Application of a pneumatic calf compression device for two hours per day, every day for 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administration of Filgrastim 10 mcg/kg every 3rd day for 30 days
Study: NCT04456972

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: One arm only
Description: Samples of plasma to analyze ctDNA
Study: NCT04426851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: BI 1358894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: BI 1358894
Study: NCT04040062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
Study: NCT01905215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003892A (formulation 1)
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003893A (formulation 2)
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003895A (formulation 3)
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003896A (formulation 4)
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003898A (formulation 5)
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003899A (formulation 6)
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule